44. 多発血管炎性肉芽腫症 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 98 / 薬物数 : 108 - (DrugBank : 28) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 81
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
AZD7986
Insmed Incorporated
2019 Phase 2 EUCTR2018-003903-21-FR France;
Abatacept
Assistance Publique - Hôpitaux de Paris
2021 Phase 2 NCT04871191 France;
Univeristy of South Florida
2016 Phase 3 EUCTR2013-005535-24-GB Australia;Canada;France;Germany;Ireland;Italy;Mexico;Spain;Sweden;Switzerland;United Kingdom;United States;
University of South Florida
2015 Phase 3 NCT02108860 Canada;Germany;Ireland;United Kingdom;United States;
Abatacept (CTLA4-Ig)
University of South Florida
2016 Phase 3 EUCTR2013-005535-24-IE Australia;Belgium;Canada;France;Germany;Ireland;Italy;Mexico;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2013-005535-24-DE Australia;Belgium;Canada;France;Germany;Ireland;Italy;Mexico;Spain;Sweden;Switzerland;United Kingdom;United States;
Alemtuzumab
Cambridge University Hospitals NHS Foundation Trust
2011 Phase 4 NCT01405807 United Kingdom;
Avacopan
CHEMOCENTRYX, INC.
2017 Phase 3 EUCTR2016-001121-14-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
ChemoCentryx, Inc.
2017 Phase 3 EUCTR2016-001121-14-SE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-NO Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-NL Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-HU Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-GB Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-ES Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-DK Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-CZ Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-BE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-AT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-IE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-FR Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-DE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
Azathioprin-ratiopharm® 25 mg Filmtabletten
Nordic Pharma France
2011 - EUCTR2011-001219-30-SE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-ES Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-CZ Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Nordic Pharma SAS
2012 - EUCTR2011-001219-30-DE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-001219-30-GB Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-SK Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Azathioprine
Assistance Publique - Hôpitaux de Paris
2018 Phase 4 NCT03164473 France;
2008 Phase 3 NCT00748644 France;
Cambridge University Hospitals NHS Foundation Trust
2013 Phase 3 NCT01697267 Australia;Canada;Czech Republic;Czechia;Ireland;Italy;Japan;New Zealand;Sweden;United Kingdom;United States;
Nordic Pharma France
2011 - EUCTR2011-001219-30-SE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-ES Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-CZ Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Nordic Pharma SAS
2012 - EUCTR2011-001219-30-DE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-001219-30-GB Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-SK Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Tokyo women'
University of Miyazaki Hospital
2014 Phase 3 JPRN-UMIN000012409 Japan,North America,South America,Australia,Europe;
s medical universityInstitute of rheumatology
Belimumab
Rachel Jones
2019 Phase 2 NCT03967925 United Kingdom;
Benralizumab
ASTRAZENECA AB
2020 Phase 3 EUCTR2019-001832-77-IT Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
AstraZeneca
2019 Phase 3 NCT04157348 Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
AstraZeneca AB
2020 Phase 3 EUCTR2019-001832-77-DE Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001832-77-GB Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001832-77-FR Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
National Jewish Health
2017 Phase 2 NCT03010436 United States;
Benralizumab, Biological: Placebo to Mepolizumab
AstraZeneca KK
2019 Phase 3 JPRN-JapicCTI-195049 Japan, North America, Europe;
Blisibimod
Anthera Pharmaceuticals
2014 Phase 2 NCT01598857 -
CCX168
CHEMOCENTRYX, INC.
2017 Phase 3 EUCTR2016-001121-14-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
ChemoCentryx, Inc.
2017 Phase 3 EUCTR2016-001121-14-SE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-NO Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-NL Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-HU Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-GB Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-ES Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-DK Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-CZ Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-BE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-AT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-IE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-FR Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-DE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
Chimeric monoclonal antibody, IgG4 subtype
InflaRx GmbH
2019 Phase 2 EUCTR2018-000768-27-SE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-NL Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-IT Belgium;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-GB Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-ES Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-DK Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-DE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-CZ Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-BE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
Corticosteroid and azathioprine
Assistance Publique - Hôpitaux de Paris
2008 Phase 3 NCT00647166 France;
Cyclophosphamide
Assistance Publique - Hôpitaux de Paris
2016 Phase 3 NCT02807103 France;
Nordic Pharma France
2011 - EUCTR2011-001219-30-SE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-ES Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-CZ Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Nordic Pharma SAS
2012 - EUCTR2011-001219-30-DE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-001219-30-GB Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-SK Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids
Nordic Pharma SAS
2011 Phase 3 NCT01446211 Czech Republic;
Cyclophosphamide/azathioprine
Assistance Publique - Hôpitaux de Paris
2021 Phase 3 NCT05030155 France;
Cyclophosphamidum
Nordic Pharma France
2011 - EUCTR2011-001219-30-SE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-ES Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-CZ Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Nordic Pharma SAS
2012 - EUCTR2011-001219-30-DE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-001219-30-GB Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-SK Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Depemokimab
GlaxoSmithKline
2022 Phase 3 NCT05263934 -
Endoxan®
Nordic Pharma France
2011 - EUCTR2011-001219-30-SE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-ES Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-CZ Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Nordic Pharma SAS
2012 - EUCTR2011-001219-30-DE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-001219-30-GB Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-SK Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Fasenra
AstraZeneca AB
2020 Phase 3 EUCTR2019-001832-77-DE Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
GALEN® tablet
InflaRx GmbH
2019 Phase 2 EUCTR2018-000768-27-NL Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-IT Belgium;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-ES Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-BE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
Glucocorticoid (GC)
InflaRx GmbH
2019 Phase 2 NCT03895801 Belgium;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Glucocorticoids
Chiba University
2014 Phase 4 NCT02198248 Japan;
Massachusetts General Hospital
2014 Phase 4 NCT02169219 United States;
Glucocorticoids (GC)
InflaRx GmbH
2019 Phase 2 EUCTR2018-000768-27-SE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-NL Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-IT Belgium;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-ES Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-DK Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-DE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-CZ Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-BE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
Glucocorticoids - Reduced Dose
University of Pennsylvania
2010 Phase 3 NCT03919825 -
Glucocorticoids - Standard Dose
University of Pennsylvania
2010 Phase 3 NCT03919825 -
Glucocorticoids [Reduced Dose]
University of Pennsylvania
2010 Phase 3 NCT00987389 Australia;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Greece;Italy;Japan;Mexico;New Zealand;Norway;Sweden;United Kingdom;United States;
Glucocorticoids [Standard Dose]
University of Pennsylvania
2010 Phase 3 NCT00987389 Australia;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Greece;Italy;Japan;Mexico;New Zealand;Norway;Sweden;United Kingdom;United States;
Gusperimus
Nordic Pharma France
2011 - EUCTR2011-001219-30-SE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-ES Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-CZ Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Nordic Pharma SAS
2012 - EUCTR2011-001219-30-DE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-001219-30-GB Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-SK Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Gusperimus + glucocorticoids
Nordic Pharma SAS
2011 Phase 3 NCT01446211 Czech Republic;
Hydroxychloroquine
Guy's and St Thomas' NHS Foundation Trust
2020 Phase 4 NCT04316494 United Kingdom;
IFX-1
InflaRx GmbH
2019 Phase 2 NCT03895801 Belgium;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-SE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-NL Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-IT Belgium;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-GB Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-ES Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-DK Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-DE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-CZ Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-BE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2018 Phase 2 NCT03712345 Canada;United States;
INS1007
Insmed Incorporated
2019 Phase 2 EUCTR2018-003903-21-FR France;
L04AC06
ASTRAZENECA AB
2020 Phase 3 EUCTR2019-001832-77-IT Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
AstraZeneca AB
2020 Phase 3 EUCTR2019-001832-77-DE Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001832-77-GB Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001832-77-FR Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
MEDI-563
ASTRAZENECA AB
2020 Phase 3 EUCTR2019-001832-77-IT Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
AstraZeneca AB
2020 Phase 3 EUCTR2019-001832-77-DE Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001832-77-GB Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001832-77-FR Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
METOJECT 10 mg/ml, solution injectable en seringue pré-remplie
Nordic Pharma France
2011 - EUCTR2011-001219-30-SE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-ES Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-CZ Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Nordic Pharma SAS
2012 - EUCTR2011-001219-30-DE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-001219-30-GB Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-SK Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
MabThera®
F. HOFFMANN - LA ROCHE LTD.
2013 - EUCTR2012-002062-13-IT Italy;Turkey;United Kingdom;United States;
F. Hoffmann-La Roche Ltd.
2013 Phase 2 EUCTR2012-002062-13-GB Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002062-13-DE Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States;
Mepolizumab
ASTRAZENECA AB
2020 Phase 3 EUCTR2019-001832-77-IT Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
Assistance Publique - Hôpitaux de Paris
2021 Phase 3 NCT05030155 France;
AstraZeneca
2019 Phase 3 NCT04157348 Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
AstraZeneca AB
2020 Phase 3 EUCTR2019-001832-77-DE Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001832-77-GB Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001832-77-FR Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
GlaxoSmithKline
2022 Phase 3 NCT05263934 -
2015 Phase 3 NCT03298061 Belgium;Canada;France;Germany;Japan;United Kingdom;United States;
2014 Phase 3 NCT02020889 Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
GlaxoSmithKline Research & Development Ltd
2014 Phase 3 EUCTR2012-004385-17-IT Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2012-004385-17-DE Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-004385-17-GB Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-004385-17-BE Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
GlaxoSmithKline, S.A.
2014 Phase 3 EUCTR2012-004385-17-ES Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
Mepolizumab, Biological: Placebo to Benralizumab
AstraZeneca KK
2019 Phase 3 JPRN-JapicCTI-195049 Japan, North America, Europe;
Metex 2,5 mg Tabletten
Nordic Pharma France
2011 - EUCTR2011-001219-30-SE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-ES Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-CZ Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Nordic Pharma SAS
2012 - EUCTR2011-001219-30-DE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-001219-30-GB Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-SK Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Methotrexate
Nordic Pharma France
2011 - EUCTR2011-001219-30-SE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-ES Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-CZ Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Nordic Pharma SAS
2012 - EUCTR2011-001219-30-DE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-001219-30-GB Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-SK Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Shanghai Zhongshan Hospital
2021 Phase 4 NCT04944524 China;
Mycophénolate mofétil
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2021 Phase 2 EUCTR2021-000679-35-FR France;
Naltrexone Hydrochloride
University of Pennsylvania
2019 Phase 2 NCT03482479 United States;
Nucala
GlaxoSmithKline Research & Development Ltd
2013 Phase 3 EUCTR2012-004385-17-GB Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
Nucala 100 mg powder for solution for injection
AstraZeneca AB
2020 Phase 3 EUCTR2019-001832-77-DE Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
Orencia
Univeristy of South Florida
2016 Phase 3 EUCTR2013-005535-24-GB Australia;Canada;France;Germany;Ireland;Italy;Mexico;Spain;Sweden;Switzerland;United Kingdom;United States;
University of South Florida
2016 Phase 3 EUCTR2013-005535-24-IE Australia;Belgium;Canada;France;Germany;Ireland;Italy;Mexico;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2013-005535-24-DE Australia;Belgium;Canada;France;Germany;Ireland;Italy;Mexico;Spain;Sweden;Switzerland;United Kingdom;United States;
Pednisone
ChemoCentryx, Inc.
2017 Phase 3 EUCTR2016-001121-14-NO Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-NL Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-HU Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-GB Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-ES Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-CZ Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-BE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-IE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-FR Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
Plaquenil - Hydroxychloroquine 200mg Film coated tablets
Guy's and St. Thomas' NHS Foundation Trust
2020 Phase 4 EUCTR2018-001268-40-GB United Kingdom;
Plasma Exchange
University of Pennsylvania
2010 Phase 3 NCT00987389 Australia;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Greece;Italy;Japan;Mexico;New Zealand;Norway;Sweden;United Kingdom;United States;
PredniSONE Tablets, USP
InflaRx GmbH
2019 Phase 2 EUCTR2018-000768-27-SE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-NL Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-IT Belgium;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-GB Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-ES Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-DK Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-DE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-CZ Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-BE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
Prednisolone
GlaxoSmithKline
2015 Phase 3 NCT03298061 Belgium;Canada;France;Germany;Japan;United Kingdom;United States;
Rachel Jones
2019 Phase 2 NCT03967925 United Kingdom;
Prednison acis®
ChemoCentryx, Inc.
2017 Phase 3 EUCTR2016-001121-14-SE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-NO Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-NL Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-HU Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-GB Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-ES Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-DK Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-CZ Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-BE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-AT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-IE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-FR Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-DE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
Prednison acis¿
CHEMOCENTRYX, INC.
2017 Phase 3 EUCTR2016-001121-14-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
Prednisone
University of Pennsylvania
2014 Phase 3 NCT01940094 Canada;United States;
RO0452294/V01
F. Hoffmann-La Roche Ltd.
2013 Phase 2 EUCTR2012-002062-13-GB Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002062-13-DE Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States;
RO0452294/V02
F. Hoffmann-La Roche Ltd.
2013 Phase 2 EUCTR2012-002062-13-GB Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002062-13-DE Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States;
Recombinant humanized monoclonal antibody specific for human IL-5
GlaxoSmithKline Research & Development Ltd
2014 Phase 3 EUCTR2012-004385-17-IT Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2012-004385-17-DE Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-004385-17-GB Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-004385-17-BE Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
GlaxoSmithKline, S.A.
2014 Phase 3 EUCTR2012-004385-17-ES Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
Remission induction therapy
Masayoshi Harigai
2018 Phase 2 JPRN-JMA-IIA00325 Japan;
Reslizumab
National Jewish Health
2017 Phase 2 NCT02947945 United States;
Rituximab
Assistance Publique - Hôpitaux de Paris
2021 Phase 2 NCT04871191 France;
2018 Phase 4 NCT03164473 France;
2016 Phase 3 NCT02807103 France;
2008 Phase 3 NCT00748644 France;
CHU de Saint-Etienne
2015 Phase 4 EUCTR2015-001807-29-FR France;
Cambridge University Hospitals NHS Foundation Trust
2013 Phase 3 NCT01697267 Australia;Canada;Czech Republic;Czechia;Ireland;Italy;Japan;New Zealand;Sweden;United Kingdom;United States;
Chiba University
2014 Phase 4 NCT02198248 Japan;
Genentech, Inc.
2012 - NCT01613599 United States;
Hoffmann-La Roche
2013 Phase 2 NCT01750697 Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States;
Hospital for Special Surgery, New York
2015 Phase 4 NCT02626845 United States;
Massachusetts General Hospital
2014 Phase 4 NCT02169219 United States;
Rachel Jones
2019 Phase 2 NCT03967925 United Kingdom;
University of Miyazaki Hospital
2014 Phase 3 JPRN-UMIN000012409 Japan,North America,South America,Australia,Europe;
Rituximab (Arm A)
Assistance Publique - Hôpitaux de Paris
2012 Phase 3 NCT01731561 France;
Rituximab (Arm B)
Assistance Publique - Hôpitaux de Paris
2012 Phase 3 NCT01731561 France;
SB-240563
GlaxoSmithKline Research & Development Ltd
2014 Phase 3 EUCTR2012-004385-17-IT Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2012-004385-17-DE Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-004385-17-GB Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-004385-17-BE Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
GlaxoSmithKline, S.A.
2014 Phase 3 EUCTR2012-004385-17-ES Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
SB-240563 (mepolizumab)
GlaxoSmithKline Research Ltd
2015 Phase 3 EUCTR2014-003162-25-GB Belgium;Canada;France;Germany;Japan;United Kingdom;
2015 Phase 3 EUCTR2014-003162-25-DE Belgium;Canada;France;Germany;Japan;United Kingdom;
2015 Phase 3 EUCTR2014-003162-25-BE Belgium;Canada;Germany;Japan;United Kingdom;United States;
Tocilizumab
Assistance Publique - Hôpitaux de Paris
2021 Phase 2 NCT04871191 France;
Tofacitinib
Shanghai Zhongshan Hospital
2021 Phase 4 NCT04944524 China;
Trimethoprim Sulfamethoxazole
University of Pennsylvania
2019 Phase 1/Phase 2 NCT03919435 United States;
Vilobelimab
InflaRx GmbH
2019 Phase 2 EUCTR2018-000768-27-SE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-NL Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-DE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-CZ Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
Vitamin D
Christian Pagnoux
2020 - NCT04280601 Canada;
Yellow Fever vaccine (17D)
University of Sao Paulo General Hospital
2018 - NCT03430388 Brazil;
Insmed Incorporated
2019 Phase 2 EUCTR2018-003903-21-FR France;
Abatacept
Assistance Publique - Hôpitaux de Paris
2021 Phase 2 NCT04871191 France;
Univeristy of South Florida
2016 Phase 3 EUCTR2013-005535-24-GB Australia;Canada;France;Germany;Ireland;Italy;Mexico;Spain;Sweden;Switzerland;United Kingdom;United States;
University of South Florida
2015 Phase 3 NCT02108860 Canada;Germany;Ireland;United Kingdom;United States;
Abatacept (CTLA4-Ig)
University of South Florida
2016 Phase 3 EUCTR2013-005535-24-IE Australia;Belgium;Canada;France;Germany;Ireland;Italy;Mexico;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2013-005535-24-DE Australia;Belgium;Canada;France;Germany;Ireland;Italy;Mexico;Spain;Sweden;Switzerland;United Kingdom;United States;
Alemtuzumab
Cambridge University Hospitals NHS Foundation Trust
2011 Phase 4 NCT01405807 United Kingdom;
Avacopan
CHEMOCENTRYX, INC.
2017 Phase 3 EUCTR2016-001121-14-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
ChemoCentryx, Inc.
2017 Phase 3 EUCTR2016-001121-14-SE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-NO Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-NL Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-HU Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-GB Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-ES Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-DK Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-CZ Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-BE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-AT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-IE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-FR Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-DE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
Azathioprin-ratiopharm® 25 mg Filmtabletten
Nordic Pharma France
2011 - EUCTR2011-001219-30-SE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-ES Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-CZ Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Nordic Pharma SAS
2012 - EUCTR2011-001219-30-DE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-001219-30-GB Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-SK Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Azathioprine
Assistance Publique - Hôpitaux de Paris
2018 Phase 4 NCT03164473 France;
2008 Phase 3 NCT00748644 France;
Cambridge University Hospitals NHS Foundation Trust
2013 Phase 3 NCT01697267 Australia;Canada;Czech Republic;Czechia;Ireland;Italy;Japan;New Zealand;Sweden;United Kingdom;United States;
Nordic Pharma France
2011 - EUCTR2011-001219-30-SE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-ES Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-CZ Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Nordic Pharma SAS
2012 - EUCTR2011-001219-30-DE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-001219-30-GB Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-SK Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Tokyo women'
University of Miyazaki Hospital
2014 Phase 3 JPRN-UMIN000012409 Japan,North America,South America,Australia,Europe;
s medical universityInstitute of rheumatology
Belimumab
Rachel Jones
2019 Phase 2 NCT03967925 United Kingdom;
Benralizumab
ASTRAZENECA AB
2020 Phase 3 EUCTR2019-001832-77-IT Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
AstraZeneca
2019 Phase 3 NCT04157348 Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
AstraZeneca AB
2020 Phase 3 EUCTR2019-001832-77-DE Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001832-77-GB Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001832-77-FR Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
National Jewish Health
2017 Phase 2 NCT03010436 United States;
Benralizumab, Biological: Placebo to Mepolizumab
AstraZeneca KK
2019 Phase 3 JPRN-JapicCTI-195049 Japan, North America, Europe;
Blisibimod
Anthera Pharmaceuticals
2014 Phase 2 NCT01598857 -
CCX168
CHEMOCENTRYX, INC.
2017 Phase 3 EUCTR2016-001121-14-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
ChemoCentryx, Inc.
2017 Phase 3 EUCTR2016-001121-14-SE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-NO Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-NL Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-HU Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-GB Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-ES Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-DK Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-CZ Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-BE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-AT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-IE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-FR Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-DE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
Chimeric monoclonal antibody, IgG4 subtype
InflaRx GmbH
2019 Phase 2 EUCTR2018-000768-27-SE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-NL Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-IT Belgium;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-GB Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-ES Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-DK Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-DE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-CZ Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-BE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
Corticosteroid and azathioprine
Assistance Publique - Hôpitaux de Paris
2008 Phase 3 NCT00647166 France;
Cyclophosphamide
Assistance Publique - Hôpitaux de Paris
2016 Phase 3 NCT02807103 France;
Nordic Pharma France
2011 - EUCTR2011-001219-30-SE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-ES Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-CZ Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Nordic Pharma SAS
2012 - EUCTR2011-001219-30-DE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-001219-30-GB Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-SK Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids
Nordic Pharma SAS
2011 Phase 3 NCT01446211 Czech Republic;
Cyclophosphamide/azathioprine
Assistance Publique - Hôpitaux de Paris
2021 Phase 3 NCT05030155 France;
Cyclophosphamidum
Nordic Pharma France
2011 - EUCTR2011-001219-30-SE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-ES Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-CZ Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Nordic Pharma SAS
2012 - EUCTR2011-001219-30-DE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-001219-30-GB Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-SK Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Depemokimab
GlaxoSmithKline
2022 Phase 3 NCT05263934 -
Endoxan®
Nordic Pharma France
2011 - EUCTR2011-001219-30-SE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-ES Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-CZ Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Nordic Pharma SAS
2012 - EUCTR2011-001219-30-DE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-001219-30-GB Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-SK Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Fasenra
AstraZeneca AB
2020 Phase 3 EUCTR2019-001832-77-DE Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
GALEN® tablet
InflaRx GmbH
2019 Phase 2 EUCTR2018-000768-27-NL Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-IT Belgium;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-ES Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-BE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
Glucocorticoid (GC)
InflaRx GmbH
2019 Phase 2 NCT03895801 Belgium;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Glucocorticoids
Chiba University
2014 Phase 4 NCT02198248 Japan;
Massachusetts General Hospital
2014 Phase 4 NCT02169219 United States;
Glucocorticoids (GC)
InflaRx GmbH
2019 Phase 2 EUCTR2018-000768-27-SE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-NL Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-IT Belgium;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-ES Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-DK Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-DE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-CZ Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-BE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
Glucocorticoids - Reduced Dose
University of Pennsylvania
2010 Phase 3 NCT03919825 -
Glucocorticoids - Standard Dose
University of Pennsylvania
2010 Phase 3 NCT03919825 -
Glucocorticoids [Reduced Dose]
University of Pennsylvania
2010 Phase 3 NCT00987389 Australia;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Greece;Italy;Japan;Mexico;New Zealand;Norway;Sweden;United Kingdom;United States;
Glucocorticoids [Standard Dose]
University of Pennsylvania
2010 Phase 3 NCT00987389 Australia;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Greece;Italy;Japan;Mexico;New Zealand;Norway;Sweden;United Kingdom;United States;
Gusperimus
Nordic Pharma France
2011 - EUCTR2011-001219-30-SE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-ES Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-CZ Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Nordic Pharma SAS
2012 - EUCTR2011-001219-30-DE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-001219-30-GB Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-SK Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Gusperimus + glucocorticoids
Nordic Pharma SAS
2011 Phase 3 NCT01446211 Czech Republic;
Hydroxychloroquine
Guy's and St Thomas' NHS Foundation Trust
2020 Phase 4 NCT04316494 United Kingdom;
IFX-1
InflaRx GmbH
2019 Phase 2 NCT03895801 Belgium;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-SE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-NL Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-IT Belgium;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-GB Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-ES Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-DK Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-DE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-CZ Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-BE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2018 Phase 2 NCT03712345 Canada;United States;
INS1007
Insmed Incorporated
2019 Phase 2 EUCTR2018-003903-21-FR France;
L04AC06
ASTRAZENECA AB
2020 Phase 3 EUCTR2019-001832-77-IT Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
AstraZeneca AB
2020 Phase 3 EUCTR2019-001832-77-DE Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001832-77-GB Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001832-77-FR Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
MEDI-563
ASTRAZENECA AB
2020 Phase 3 EUCTR2019-001832-77-IT Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
AstraZeneca AB
2020 Phase 3 EUCTR2019-001832-77-DE Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001832-77-GB Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001832-77-FR Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
METOJECT 10 mg/ml, solution injectable en seringue pré-remplie
Nordic Pharma France
2011 - EUCTR2011-001219-30-SE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-ES Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-CZ Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Nordic Pharma SAS
2012 - EUCTR2011-001219-30-DE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-001219-30-GB Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-SK Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
MabThera®
F. HOFFMANN - LA ROCHE LTD.
2013 - EUCTR2012-002062-13-IT Italy;Turkey;United Kingdom;United States;
F. Hoffmann-La Roche Ltd.
2013 Phase 2 EUCTR2012-002062-13-GB Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002062-13-DE Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States;
Mepolizumab
ASTRAZENECA AB
2020 Phase 3 EUCTR2019-001832-77-IT Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
Assistance Publique - Hôpitaux de Paris
2021 Phase 3 NCT05030155 France;
AstraZeneca
2019 Phase 3 NCT04157348 Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
AstraZeneca AB
2020 Phase 3 EUCTR2019-001832-77-DE Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001832-77-GB Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001832-77-FR Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
GlaxoSmithKline
2022 Phase 3 NCT05263934 -
2015 Phase 3 NCT03298061 Belgium;Canada;France;Germany;Japan;United Kingdom;United States;
2014 Phase 3 NCT02020889 Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
GlaxoSmithKline Research & Development Ltd
2014 Phase 3 EUCTR2012-004385-17-IT Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2012-004385-17-DE Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-004385-17-GB Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-004385-17-BE Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
GlaxoSmithKline, S.A.
2014 Phase 3 EUCTR2012-004385-17-ES Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
Mepolizumab, Biological: Placebo to Benralizumab
AstraZeneca KK
2019 Phase 3 JPRN-JapicCTI-195049 Japan, North America, Europe;
Metex 2,5 mg Tabletten
Nordic Pharma France
2011 - EUCTR2011-001219-30-SE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-ES Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-CZ Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Nordic Pharma SAS
2012 - EUCTR2011-001219-30-DE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-001219-30-GB Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-SK Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Methotrexate
Nordic Pharma France
2011 - EUCTR2011-001219-30-SE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-ES Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-CZ Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Nordic Pharma SAS
2012 - EUCTR2011-001219-30-DE Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-001219-30-GB Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-001219-30-SK Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
Shanghai Zhongshan Hospital
2021 Phase 4 NCT04944524 China;
Mycophénolate mofétil
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2021 Phase 2 EUCTR2021-000679-35-FR France;
Naltrexone Hydrochloride
University of Pennsylvania
2019 Phase 2 NCT03482479 United States;
Nucala
GlaxoSmithKline Research & Development Ltd
2013 Phase 3 EUCTR2012-004385-17-GB Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
Nucala 100 mg powder for solution for injection
AstraZeneca AB
2020 Phase 3 EUCTR2019-001832-77-DE Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States;
Orencia
Univeristy of South Florida
2016 Phase 3 EUCTR2013-005535-24-GB Australia;Canada;France;Germany;Ireland;Italy;Mexico;Spain;Sweden;Switzerland;United Kingdom;United States;
University of South Florida
2016 Phase 3 EUCTR2013-005535-24-IE Australia;Belgium;Canada;France;Germany;Ireland;Italy;Mexico;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2013-005535-24-DE Australia;Belgium;Canada;France;Germany;Ireland;Italy;Mexico;Spain;Sweden;Switzerland;United Kingdom;United States;
Pednisone
ChemoCentryx, Inc.
2017 Phase 3 EUCTR2016-001121-14-NO Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-NL Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-HU Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-GB Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-ES Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-CZ Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-BE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-IE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-FR Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
Plaquenil - Hydroxychloroquine 200mg Film coated tablets
Guy's and St. Thomas' NHS Foundation Trust
2020 Phase 4 EUCTR2018-001268-40-GB United Kingdom;
Plasma Exchange
University of Pennsylvania
2010 Phase 3 NCT00987389 Australia;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Greece;Italy;Japan;Mexico;New Zealand;Norway;Sweden;United Kingdom;United States;
PredniSONE Tablets, USP
InflaRx GmbH
2019 Phase 2 EUCTR2018-000768-27-SE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-NL Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-IT Belgium;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-GB Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-ES Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-DK Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-DE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-CZ Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-BE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
Prednisolone
GlaxoSmithKline
2015 Phase 3 NCT03298061 Belgium;Canada;France;Germany;Japan;United Kingdom;United States;
Rachel Jones
2019 Phase 2 NCT03967925 United Kingdom;
Prednison acis®
ChemoCentryx, Inc.
2017 Phase 3 EUCTR2016-001121-14-SE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-NO Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-NL Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-HU Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-GB Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-ES Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-DK Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-CZ Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-BE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001121-14-AT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-IE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-FR Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-001121-14-DE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
Prednison acis¿
CHEMOCENTRYX, INC.
2017 Phase 3 EUCTR2016-001121-14-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
Prednisone
University of Pennsylvania
2014 Phase 3 NCT01940094 Canada;United States;
RO0452294/V01
F. Hoffmann-La Roche Ltd.
2013 Phase 2 EUCTR2012-002062-13-GB Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002062-13-DE Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States;
RO0452294/V02
F. Hoffmann-La Roche Ltd.
2013 Phase 2 EUCTR2012-002062-13-GB Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002062-13-DE Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States;
Recombinant humanized monoclonal antibody specific for human IL-5
GlaxoSmithKline Research & Development Ltd
2014 Phase 3 EUCTR2012-004385-17-IT Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2012-004385-17-DE Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-004385-17-GB Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-004385-17-BE Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
GlaxoSmithKline, S.A.
2014 Phase 3 EUCTR2012-004385-17-ES Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
Remission induction therapy
Masayoshi Harigai
2018 Phase 2 JPRN-JMA-IIA00325 Japan;
Reslizumab
National Jewish Health
2017 Phase 2 NCT02947945 United States;
Rituximab
Assistance Publique - Hôpitaux de Paris
2021 Phase 2 NCT04871191 France;
2018 Phase 4 NCT03164473 France;
2016 Phase 3 NCT02807103 France;
2008 Phase 3 NCT00748644 France;
CHU de Saint-Etienne
2015 Phase 4 EUCTR2015-001807-29-FR France;
Cambridge University Hospitals NHS Foundation Trust
2013 Phase 3 NCT01697267 Australia;Canada;Czech Republic;Czechia;Ireland;Italy;Japan;New Zealand;Sweden;United Kingdom;United States;
Chiba University
2014 Phase 4 NCT02198248 Japan;
Genentech, Inc.
2012 - NCT01613599 United States;
Hoffmann-La Roche
2013 Phase 2 NCT01750697 Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States;
Hospital for Special Surgery, New York
2015 Phase 4 NCT02626845 United States;
Massachusetts General Hospital
2014 Phase 4 NCT02169219 United States;
Rachel Jones
2019 Phase 2 NCT03967925 United Kingdom;
University of Miyazaki Hospital
2014 Phase 3 JPRN-UMIN000012409 Japan,North America,South America,Australia,Europe;
Rituximab (Arm A)
Assistance Publique - Hôpitaux de Paris
2012 Phase 3 NCT01731561 France;
Rituximab (Arm B)
Assistance Publique - Hôpitaux de Paris
2012 Phase 3 NCT01731561 France;
SB-240563
GlaxoSmithKline Research & Development Ltd
2014 Phase 3 EUCTR2012-004385-17-IT Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2012-004385-17-DE Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-004385-17-GB Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-004385-17-BE Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
GlaxoSmithKline, S.A.
2014 Phase 3 EUCTR2012-004385-17-ES Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
SB-240563 (mepolizumab)
GlaxoSmithKline Research Ltd
2015 Phase 3 EUCTR2014-003162-25-GB Belgium;Canada;France;Germany;Japan;United Kingdom;
2015 Phase 3 EUCTR2014-003162-25-DE Belgium;Canada;France;Germany;Japan;United Kingdom;
2015 Phase 3 EUCTR2014-003162-25-BE Belgium;Canada;Germany;Japan;United Kingdom;United States;
Tocilizumab
Assistance Publique - Hôpitaux de Paris
2021 Phase 2 NCT04871191 France;
Tofacitinib
Shanghai Zhongshan Hospital
2021 Phase 4 NCT04944524 China;
Trimethoprim Sulfamethoxazole
University of Pennsylvania
2019 Phase 1/Phase 2 NCT03919435 United States;
Vilobelimab
InflaRx GmbH
2019 Phase 2 EUCTR2018-000768-27-SE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-NL Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-DE Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
2019 Phase 2 EUCTR2018-000768-27-CZ Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;
Vitamin D
Christian Pagnoux
2020 - NCT04280601 Canada;
Yellow Fever vaccine (17D)
University of Sao Paulo General Hospital
2018 - NCT03430388 Brazil;